MassHealth hopes to transition to ACO to control costs

A proposed overhaul of Massachusetts’Medicaid program, MassHealth, from Mass. Gov. Charlie Baker’s administration would transition the program from fee-for-service to an accountable care organization (ACO) model in an effort to keep costs down.

The plan also includes negotiating with the federal government to get $1.5 billion for providers to move toward ACOs. The state would contribute $250 million through an increase in a fee paid by hospitals, offset by an equal annual increase in Medicaid reimbursements to hospitals, according to MassLive.com.

Baker’s administration cited the growing costs of MassHealth as the reason for the change, saying the $15 billion program now takes up nearly 40 percent of the state’s annual budget while only covering a fourth of the state’s residents.

“The current structure is not sustainable," said Massachusetts Secretary of Health and Human Services Marylou Sudders to MassLive. "It's the same structure we had since the mid-1990s. Rumor has it healthcare has changed since the mid-'90s."

The alternative, according to Sudders, would be reducing benefit programs.

The plan doesn’t include any hard estimate as to how much the state will save by transitioning to ACOs, but it does cover additional care not typically included in ACO models in other states, such as substance abuse treatment.

“We're optimistic the plan recognizes the centrality of behavioral health in a way state government hasn't in the past," Vic DeGravio, president of the Association for Behavioral Healthcare, said to MassLive.

The state’s Executive Office of Health and Human Services (EOHHS) expects to select ACOs by December, in time for the full program to launch in late 2017. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.